266 related articles for article (PubMed ID: 25981988)
1. Upfront treatment of high-risk neuroblastoma with a combination of 131I-MIBG and topotecan.
Kraal KC; Tytgat GA; van Eck-Smit BL; Kam B; Caron HN; van Noesel M
Pediatr Blood Cancer; 2015 Nov; 62(11):1886-91. PubMed ID: 25981988
[TBL] [Abstract][Full Text] [Related]
2. Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients.
Kraal KC; Bleeker GM; van Eck-Smit BL; van Eijkelenburg NK; Berthold F; van Noesel MM; Caron HN; Tytgat GA
Eur J Cancer; 2017 May; 76():188-196. PubMed ID: 28329731
[TBL] [Abstract][Full Text] [Related]
3. 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma.
French S; DuBois SG; Horn B; Granger M; Hawkins R; Pass A; Plummer E; Matthay K
Pediatr Blood Cancer; 2013 May; 60(5):879-84. PubMed ID: 23024113
[TBL] [Abstract][Full Text] [Related]
4. Peripheral Stem Cell Apheresis is Feasible Post
Kraal KCJM; Timmerman I; Kansen HM; van den Bos C; Zsiros J; van den Berg H; Somers S; Braakman E; Peek AML; van Noesel MM; van der Schoot CE; Fiocco M; Caron HN; Voermans C; Tytgat GAM
Clin Cancer Res; 2019 Feb; 25(3):1012-1021. PubMed ID: 30314967
[TBL] [Abstract][Full Text] [Related]
5. 131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study.
Yanik GA; Villablanca JG; Maris JM; Weiss B; Groshen S; Marachelian A; Park JR; Tsao-Wei D; Hawkins R; Shulkin BL; Jackson H; Goodarzian F; Shimada H; Courtier J; Hutchinson R; Haas-Koga D; Hasenauer CB; Czarnecki S; Katzenstein HM; Matthay KK
Biol Blood Marrow Transplant; 2015 Apr; 21(4):673-81. PubMed ID: 25639769
[TBL] [Abstract][Full Text] [Related]
6. Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma.
Kraal KC; van Dalen EC; Tytgat GA; Van Eck-Smit BL
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010349. PubMed ID: 28429876
[TBL] [Abstract][Full Text] [Related]
7. Feasibility of Busulfan Melphalan and Stem Cell Rescue After 131I-MIBG and Topotecan Therapy for Refractory or Relapsed Metastatic Neuroblastoma: The French Experience.
Ferry I; Kolesnikov-Gauthier H; Oudoux A; Cougnenc O; Schleiermacher G; Michon J; Bogart E; Chastagner P; Proust S; Valteau-Couanet D; Defachelles AS
J Pediatr Hematol Oncol; 2018 Aug; 40(6):426-432. PubMed ID: 29642099
[TBL] [Abstract][Full Text] [Related]
8. Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma.
Gaze MN; Chang YC; Flux GD; Mairs RJ; Saran FH; Meller ST
Cancer Biother Radiopharm; 2005 Apr; 20(2):195-9. PubMed ID: 15869455
[TBL] [Abstract][Full Text] [Related]
9. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.
Matthay KK; Tan JC; Villablanca JG; Yanik GA; Veatch J; Franc B; Twomey E; Horn B; Reynolds CP; Groshen S; Seeger RC; Maris JM
J Clin Oncol; 2006 Jan; 24(3):500-6. PubMed ID: 16421427
[TBL] [Abstract][Full Text] [Related]
10. Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age.
de Kraker J; Hoefnagel KA; Verschuur AC; van Eck B; van Santen HM; Caron HN
Eur J Cancer; 2008 Mar; 44(4):551-6. PubMed ID: 18267358
[TBL] [Abstract][Full Text] [Related]
11. Experimental treatment of neuroblastoma using [131I]meta-iodobenzylguanidine and topotecan in combination.
McCluskey AG; Boyd M; Pimlott SL; Babich JW; Gaze MN; Mairs RJ
Br J Radiol; 2008 Oct; 81 Spec No 1():S28-35. PubMed ID: 18819996
[TBL] [Abstract][Full Text] [Related]
12. The potential role of pretransplant MIBG diagnostic scintigraphy in targeted administration of 131I-MIBG accompanied by ASCT for high-risk and relapsed neuroblastoma: a pilot study.
Hamidieh AA; Beiki D; Paragomi P; Fallahi B; Behfar M; Fard-Esfahani A; Hosseini AS; Shamshiri A; Eftekhari M; Ghavamzadeh A
Pediatr Transplant; 2014 Aug; 18(5):510-7. PubMed ID: 24814429
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of
Sevrin F; Kolesnikov-Gauthier H; Cougnenc O; Bogart E; Schleiermacher G; Courbon F; Gambart M; Giraudet AL; Corradini N; Badel JN; Rault E; Oudoux A; Deley MCL; Valteau-Couanet D; Defachelles AS
Pediatr Blood Cancer; 2023 Nov; 70(11):e30615. PubMed ID: 37574821
[TBL] [Abstract][Full Text] [Related]
14. Engraftment after myeloablative doses of 131I-metaiodobenzylguanidine followed by autologous bone marrow transplantation for treatment of refractory neuroblastoma.
Goldberg SS; DeSantes K; Huberty JP; Price D; Hasegawa BH; Reynolds CP; Seeger RC; Hattner R; Matthay KK
Med Pediatr Oncol; 1998 Jun; 30(6):339-46. PubMed ID: 9589082
[TBL] [Abstract][Full Text] [Related]
15. Incorporation of high-dose
Lee JW; Lee S; Cho HW; Ma Y; Yoo KH; Sung KW; Koo HH; Cho EJ; Lee SK; Lim DH
J Hematol Oncol; 2017 May; 10(1):108. PubMed ID: 28511709
[TBL] [Abstract][Full Text] [Related]
16. Megatherapy combining I(131) metaiodobenzylguanidine and high-dose chemotherapy with haematopoietic progenitor cell rescue for neuroblastoma.
Miano M; Garaventa A; Pizzitola MR; Piccolo MS; Dallorso S; Villavecchia GP; Bertolazzi C; Cabria M; De Bernardi B
Bone Marrow Transplant; 2001 Mar; 27(6):571-4. PubMed ID: 11319584
[TBL] [Abstract][Full Text] [Related]
17. Dosimetry-based high-activity therapy with
Genolla J; Rodriguez T; Minguez P; Lopez-Almaraz R; Llorens V; Echebarria A
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1567-1575. PubMed ID: 30838430
[TBL] [Abstract][Full Text] [Related]
18. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma.
Matthay KK; DeSantes K; Hasegawa B; Huberty J; Hattner RS; Ablin A; Reynolds CP; Seeger RC; Weinberg VK; Price D
J Clin Oncol; 1998 Jan; 16(1):229-36. PubMed ID: 9440747
[TBL] [Abstract][Full Text] [Related]
19. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma.
Yanik GA; Levine JE; Matthay KK; Sisson JC; Shulkin BL; Shapiro B; Hubers D; Spalding S; Braun T; Ferrara JL; Hutchinson RJ
J Clin Oncol; 2002 Apr; 20(8):2142-9. PubMed ID: 11956276
[TBL] [Abstract][Full Text] [Related]
20. Preoperative [131I]metaiodobenzylguanidine therapy of neuroblastoma at diagnosis ("MIBG de novo").
Hoefnagel CA; de Kraker J; Voûte PA; Valdés Olmos RA
J Nucl Biol Med (1991); 1991; 35(4):248-51. PubMed ID: 1823828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]